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SUMMARY
The management of sporadic vestibular schwannoma (VS) has evolved in the last decades. The aim of this study was to analyse the evolu-
tion in surgical outcomes of VSs operated by a neurotological team between 1990 and 2006 by different approaches. A monocentric retro-
spective review of medical charts of 1006 patients was performed. In order to assess eventual changes and progress, the 17-years period was 
divided in three periods, each one comprehending 268 VS (1990-1996), 299 VS (1997-2001), and 439 VS (2002-2006). Mean follow-up 
was 5.9 ± 2.4 years. Overall, complete VS removal was achieved in 99.4% of cases. Mortality rate was 0.3%, meningitis and CSF leaks 
were observed in 1.2 % and 9 % of the cases, respectively. CSF leakage decreased from 11.6% to 7.1% between the first and last period (p < 
0.01) as well as revision surgery from 3.4 % to 0.9 % (p < 0.05). Facial nerve was anatomically preserved in 97.7% of cases. At one year, a 
good facial nerve function was observed in 85.1% of patients (grade I and II of House-Brackmann grading scale), which ranged between the 
first and last period from 78.4% to 87.6% (p <0.05). At one year, hearing preservation was obtained in 61.6% of patients, which increased 
from the first period to the last one from 50.9% to 69.0% (p < 0.05) (class A+B+C from the AAO-HNS classification). Useful hearing (class 
A+B) was observed in 33.5% of cases overall, with 21.8% and 42% in the first and last period, respectively (p < 0.01). Surgical outcomes 
of sporadic vestibular schwannoma have improved concerning facial nerve function outcomes, hearing preservation and cerebrospinal fluid 
(CSF) leaks, mainly due to the neuro-otological team’s experience. Functional results after complete microsurgical removal of large VS 
depend on experience gained on small VS removal.
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RIASSUNTO
La gestione dello schwannoma vestibolare (SV) sporadico si è gradualmente evoluta negli ultimi decenni. Lo scopo di questo studio è di 
analizzare l’evoluzione negli esiti chirurgici dell’exeresi di queste lesioni, realizzata da un team neurotologico tra il 1990 e il 2006, at-
traverso differenti approcci. È stata eseguita una revisione retrospettica monocentrica dei dati clinici di 1006 pazienti. Al fine di valutare 
eventuali modifiche e progressi, il periodo di 17 anni è stato diviso in tre periodi, ciascuno comprendente rispettivamente 268 SV (1990-
1996), 299 SV (1997-2001), e 439 SV (2002-2006). Il follow-up medio è stato di 5,9 ± 2,4 anni. Complessivamente l’asportazione totale è 
stata ottenuta nel 99,4% dei casi. Il tasso di mortalità è stato dello 0,3%, la meningite e la perdita di liquido cefalo rachidiano (LCR) sono 
stati osservati nel 1,2% e il 9% dei casi, rispettivamente. La frequenza della perdita di LCR è diminuita dal 11,6% al 7,1% tra il primo e 
dell’ultimo periodo (p < 0,01) e la revisione chirurgica dal 3,4% al 0,9% (p < 0,05). Il nervo facciale è stato anatomicamente conservato 
nel  97,7% dei casi. Ad un anno, una buona funzione del nervo facciale è stata osservata nel 85,1% dei pazienti (I e II grado House-
Brackmann), con una variazione tra il primo e l’ultimo periodo che andava dal 78,4% al 87,6% (p < 0,05). Ad un anno post-operatorio la 
conservazione dell’udito è stata ottenuta nel 61,6% dei pazienti, passando dal 50,9% del primo periodo, al 69,0% del periodo piú recente 
(p < 0,05) (classe A + B + C dalla classificazione AAO-HNS). L’udito utile (classe A + B) è stato conservato nel 33,5% dei casi comples-
sivamente, con percentuali comprese tra il 21,8% e 42% nel primo e nell’ultimo periodo rispettivamente (p < 0,01). Gli esiti chirurgici 
dell’asportazion dello schwannoma vestibolare sporadico sono migliorati negli anni per quanto riguarda i risultati funzionali del nervo 
facciale, la conservazione dell’udito, le perdite di liquido cefalorachidiano, principalmente grazie all’esperienza del team neurotologico. I 
risultati funzionali dopo la rimozione microchirurgica completa SV di grandi dimensioni dipendono dall’ esperienza maturata sulle lesioni 
di piccole dimensioni.
PAROLE CHIAVE: Nervo facciale • Schwannoma vestibulare • Translabirintico • Udito
Acta Otorhinolaryngol Ital 2016;36:408-414
Surgical treatment of sporadic vestibular schwannoma in a series of 1006 patients
409
Introduction
Complete microsurgical excision of sporadic vestibular 
schwannoma (VS) has been advocated for all tumour 
sizes, up to the beginning of this century. Because of the 
development of magnetic resonance imaging (MRI) tech-
niques, which have been easier to obtain, a wait and scan 
policy was introduced in the early 1990s 1. Since then, 
the introduction of radiotherapy in stereotaxic conditions, 
mainly by gamma-knife, invigorates the debate concern-
ing the microsurgical removal of small and middle-sized 
VS, especially in the elderly when VSs are progressive. 
Besides, radiosurgery has become more popular as far as 
the doses have been reduced to limit the toxic effects of 
radioactive agents on neurological structures, and it has 
been proposed, in case of large VS, to reduce the posterior 
fossa extension of the tumour by a partial microsurgical 
excision before irradiating the remaining tumour 2.
Nevertheless, recent studies have described advances in 
surgical techniques and devices, which in association with 
the improvement of surgeon’s experience may have led 
to a gradually decreasing surgical mortality and morbidi-
ty. Hence, the modern surgical goals of sporadic VS have 
changed to achieve higher complete tumour removal, with 
higher rates of facial nerve (FN) function and hearing lev-
el preservation, lower mortality and neurological morbid-
ity incidence 3-8. 
Good postoperative outcomes depend on several factors 
including tumour size, surgical approaches, intraoperative 
nerve monitoring, cranial nerve displacement pattern and 
tumour adherence to neurological structures, in addition to 
surgical experience 4-12. However, few authors have reviewed 
surgical outcomes of large series of more than 500 cases 4-8 13.
The aim of this study is to report the surgical outcomes 
in a large series of more than 1000 sporadic VS operated 
by the same neuro-otological team over a 17-year period.
Materials and methods
A monocentric retrospective review was performed on 
medical charts of 1006 consecutive patients operated for 
sporadic VS removal between January 1990 and Decem-
ber 2006. Patients with neurofibromatosis Type II (NF2) 
were excluded. Data were extracted pertaining to the fol-
lowing variables: patient demographics; tumour localisa-
tion; clinical and imaging features; facial nerve function, 
hearing levels, and details of surgical intervention. Patient 
demographics are reported in Table I. In order to investi-
gate the changes and eventual progresses of the surgical 
management during the 17-year period, 3 consecutive pe-
riods were explored separately: the earlier period (period 
1) between 1990 and 1996, the intermediate period (pe-
riod 2) between 1997 and 2001 and the last period group 
(period 3) between 2002 and 2006. Mean follow-up was 
5.9 ± 2.4 years.
All surgical procedures were performed by the same neu-
ro-otological team (AR and MK, neurosurgeons; OS otol-
ogist) in a tertiary referral centre. 
The FN function was assessed using the House-Brack-
mann (HB) grading system 14. HB grade I or II, grade III 
or IV, and grade V or VI were defined as good, mild and 
poor FN function respectively. Intraoperative facial nerve 
monitoring (NIM and NIM II, Medtronic, Xomed, Jack-
sonville, FL, USA) was routinely used.
All patients completed a series of audiovestibular as-
sessments including pure tone audiometry, intelligibility 
scores, auditory brainstem evoked responses and calor-
ic and videonistagmography testing. Hearing level was 
evaluated using the American Academy of Otolaryngol-
ogy-Head and Neck surgery (AAO-HNS) guidelines and 
staged in 4 classes 15. Preservation of hearing was calcu-
lated as the sum of class A+B+C and a serviceable hear-
ing as the sum of class A+B. Tumour size measurement 
was based on the largest extrameatal diameter in the cer-
ebello-pontine angle (CPA) from T1-weighted MRI with 
gadolinium. The tumours were divided into 4 stages 10-12: 
stage I (intracanalicular), stage II (inferior or equal to 15 
mm in the CPA), stage 3 (from 16 to 30 mm in the CPA) 
and stage IV (superior to 30 mm in the CPA).
We analysed functional surgical outcomes among the 
three groups considering the following variables: com-
pleteness of tumour removal, intraoperative FN status, 
postoperative FN outcomes at one year, hearing preserva-
tion, CSF leakages and other complications.
Statistical methods
Data are expressed as mean ± SD. All data were analysed 
with the software SPSS 19.0. The χ2 and Fisher’s exact 
tests were used to compare surgical outcomes and the 
general characteristics of the three groups. Significance 
was considered at p < 0.05.
Results
Preoperative clinical and radiological data are reported in 
Table I. No significant difference in demographics was ob-
served among the patients in the three periods. Mean age 
was 55.6 ± 13.6 years with a sex ratio of 0.88:1. VS was 
revealed by progressive or a sudden hearing loss in 84.3% 
or 10.7% of cases, respectively. Vertigo and tinnitus were 
present in 33.7% and 38.9% of cases, respectively.
Preoperative FN function was normal or subnormal in 
98.8 % cases. Trigeminal nerve dysfunction was observed 
in 17% of patients. Pre-operative useful hearing was in 
41.7% and dead ear or absence of intelligibility in 35.5%. 
In the different groups, intracanalicular VS ranged from 
7.7% to 9. %, stage 2 VS from 35.4% to 46.2% and large 
VS (stage 3 and 4) from 44.9 to 54.9%. 
The surgical approach was chosen depending on: (i) tu-
mour size, its extension into the CPA anterior to the inter-
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nal auditory meatus (IAM), at the IAM fundus, or intra-
cochlear extension; (ii) ipsilateral and contralateral hearing 
level; (iii) general status and patients’ expectations. Pre-
cisely, a translabyrinthine approach (TLa) for stage 3 and 
4 VS or stage 1 and 2 VS with class C or D hearing loss; 
transotic approach (TOa) for stage 3 and 4 VS with exten-
sion anterior to the IAM or any stage VS with intracochlear 
extension; retrosigmoid approach (RSa) for stage 1 and 2 
VS with class A or B hearing loss and IAM fundus free 
of tumour; and middle fossa approach (MFa) for stage 1 
VS with class A or B hearing level. The extent of tumour 
resection was defined accordingly to the Acoustic Neuroma 
Consensus on System Reporting Results 16.
Table II shows the approaches performed in relation to the 
size of VS. It appears that in few stages 2 MSa was chosen as 
well as RSa in few stages 3; TOa was mainly used in stage 4 
VS. These approaches were differently used as a function of 
the period. More TLa and few RSa were performed during 
the early period as compared to the last one. More TOa and 
less MFa were performed during the last period.
Intraoperative FN status and postoperative FN function
Anatomical FN integrity was preserved in 983 patients 
(97.7%). Seven hundred and twenty-four patients (72.0%) 
completed the postoperative FN function evaluation at 
1-year. There were 616 (85.1%), 103 (14.2%) and 5 (0.7%) 
patients with, respectively, good, medium and poor post-
Table II. Surgical approaches according to tumour stage.
Tumour stage
1
(n = 88) 
2
(n = 434)
3
(n = 298)
4
(n = 186)
TLa 27
(30.7%)
242
(55.8%)
259
(86.9%)
120
(64.5%)
TOa 10
(11.4%)
7
(1.6%)
17
(5.7%)
66
(35.5%)
RSa 1
(1.1%)
158
(36.4%)
22
(7.4%)
-
MFa 50
(56.8%)
27
(6.2%)
- -
TLa: translabyrinthine approach; TOa: transotic approach; RSA: retrosigmoid 
approach; MFA: middle fossa approach.
Table I. Preoperative clinical and radiological data of patients.
Characteristic Period 1
1990-1996
 n = 268
Period 2
1997-2001 
n = 299
Period 3
2002-2006, 
n = 439
Total
1990-2006 
n = 1006
Male 105 151 216 472 (46.9%)
Female 163 148 223 534 (53.1%)
Left side 145 177 320 642 (63.8%)
Right side 123 122 119 364 (36.2%)
Age (yr) 64.2 ± 13.8 57.4 ± 12.4 55.3 ± 13.1 51.3 ± 13.6
Tumour size (mm) 19.0 ± 12.5 16.9 ± 10.8 16.4 ± 11.9 17.2 ± 11.7 
Tumour Stage
1 26 (9.7%) 23 (7.7%) 39 (8.9%) 88 (8.7%)
2 95 (35.4%) 136 (45.5%) 203 (46.2%) 434 (43.1%)
3 91 (34.0%) 97 (32.4%) 110 (25.1%) 298 (29.6%)
4 56 (20.9%) 43 (14.4%) 87 (19.8%) 186 (18.5%)
Trigeminal nerve dysfunction 55 (20.5%) 47 (15.7%) 69 )15.7%) 171 (17.0%)
Facial nerve 
HB I-II 266 (99.3%) 298 (99.7%) 430 (97.9%) 994 (98.8%)
HB III-IV 1 (0.4%) 1 (0.3%) 9 (2.1%) 11 (1.1%)
HB V-VI 1 (0.4%) - - 1 (0.1%)
Tinnitus 126 (47.0%) 133 (44.5%) 132 (30.1%) 391 (38.9%)
Vertigo 107 (39.9%) 128 (42.8%) 104 (23.7%) 339 (33.7%)
Otalgia 1 (0.4%) 1 (0.3%) 8 (1.8%) 10 (1.0%)
Hearing loss
Progressive 223 (83.2%) 247 (82.6%) 378 (86.1%) 848 (84.3%)
Sudden 30 (11.2%) 32 (10.7%) 46 (10.5%) 108 (10.7%)
Class A 54 (20.1%) 68 (22.7%) 72 (16.4%) 194 (19.3%)
Class B 56 (20.9%) 84 (28.1%) 85 (19.4%) 225 (22.4%)
Class C 68 (25.4%) 70 (23.4%) 92 (21.0%) 230 (22.9%)
Class D 90 (33.6%) 77 (25.8%) 190 (43.3%) 357 (35.5%)
Headache 18 (6.7%) 16 (5.4%) 14 (3.2%) 48 (4.8%)
Intracranial hypertension 7 (2.6%) 1 (0.3%) 3 (0.7%) 11 (1.1%)
HB: House-Brackmann facial nerve grading system.
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operative FN function. The good FN function rate was in-
versely proportional to the tumour size (Table III): 91.7% 
in stage 1, 86.2% in stage 2, 84.9% in stage 3 and 79.9% 
in stage 4 (good FN function between stage 1 and 4 had 
significant different, p = 0.04). Good FN function was seen 
87.7% of cases in TLa, 82.0% in TOa, 81.1% in RSa and 
78.1% in MFa, and it was higher in TLa than that in MFa 
(p = 0.048). Furthermore, the good FN function in period 1 
was lower than that in period 3 (78.4% vs 87.6%, p = 0.02).
Out of 23 FNs interrupted during surgery, 13 (56.5%) 
were repaired by end-to-end anastomosis and 10 (43.5%) 
by great auricular nerve graft with fibrin glue 17.
Hearing results
Out of 419 patients with a preoperative hearing level class 
A, B and C, 245 patients (58.5%) underwent tumour re-
moval via RSa or MFa (Table IV). Overall, the hearing 
preservation rate was 61.6% (151 patients), and a service-
able hearing level was achieved in 82 patients (33.5%). 
Both these two rates in group 3 were higher than those 
in groups 1 and 2 (hearing preservation rate: 69.0% vs 
50.9%, p = 0.028; serviceable hearing preservation rate: 
42.2% vs 21.8%, p = 0.01).
Complications 
The complications occurred in the present series are report-
ed in Table V. CSF leakage occurred in 91 patients (9.0%), 
72 of whom were treated conservatively with pressure 
dressings and lumbar drainage, and 19 underwent revision 
surgery. The management of CSF leakage was decided on 
the base of the cerebrospinal fluid pressure value18. Accord-
ing to the tumour size classification, the incidence of CSF 
leakage was 5.0% (4 cases) in stage 1, 7.4% (32 cases) in 
stage 2, 9.5% (28 cases) in stage 3 and 14.7% (27 cases) in 
stage 4. According to the surgical approaches, it occurred 
in 7.9% (51 cases) in TLa, 12.2% (12 cases) in TOa, 10.5% 
(19 cases) in RSa and 11.7% (9 cases) in MFa. 
We used four techniques of wound closure to prevent CSF 
leakage during the three consecutive periods 19: 1) place-
ment of the fascia graft on the dural defect and afterwards 
fat tissue placement over the fascia; 2) large musculoperi-
osteal flap to compress the fascia-fat complex; 3) fat tis-
sue directly placed into the operative cavity without fascia 
graft, then covered with a musculoperiosteal flap; 4) fat 
tissue directly placed into the operative cavity and hold 
in place with a titanium plate fixed to the mastoid bone. 
The incidence of CSF leakage decreased along the three 
periods: 11.6%, 9.7% and 7.1% in the early, intermediate 
and last periods, respectively. Likewise, the incidence of 
postoperative septic meningitis decreased throughout the 
different periods: 1.9%, 1.3% and 0.7% in early, interme-
diate and last periods, respectively.
The mortality rate reported in this series was 0.3% (3 pa-
tients). One patient with stage 3 VS deceased of postop-
erative CPA hematoma. The two other patients presenting 
a stage 4 VS deceased of postoperative pulmonary embo-
lism and cerebral haemorrhage, respectively. 
Twelve patients (1.2%) with a total tumour resection pre-
sented a recurrence, detected through the routine annual 
MRI. The mean interval between surgery and recurrence was 
2.8 ± 1.9 years (range 1-6 years). The mean diameter of the 
Table III. Postoperative facial nerve function at 1 year.
HB Grade I-II 
(%)
HB Grade III-IV
 (%)
HB Grade V-VI
 (%)
Tumour stage
1 (n = 60) 55 (91.7) 5 (8.3) -
2 (n = 333) 287 (86.2) 46 (13.8) -
3 (n = 192) 163 (84.9) 27 (14.1) 2 (1.0)
4 (n = 139) 111 (79.9) 25 (18.0) 3 (2.2)
Surgical approach
TLa (n = 456) 400 (87.7) 51 (11.2) 5 (1.1)
TOa (n = 61) 50 (82.0) 11 (18.0) -
RSa (n = 143) 116 (81.1) 27 (18.9) -
MFa (n = 64) 50 (78.1) 14 (21.9) -
Surgical period
Period 1 (1990-1996, n = 88) 69 (78.4) 18 (20.5) 1 (1.1)
Period 2 (1997-2001, n = 241) 201 (83.4) 38 (15.8) 2 (0.8)
Period 3 (2002-2006, n = 395) 346 (87.6) 47 (11.9) 2 (0.5)
HB: House-Brackmann facial nerve grading system; TLa: translabyrinthine approach; TOa: transotic approach; RSa: retrosigmoid approach; MFa: middle fossa approach.
Table IV. Hearing results at the last follow-up (n = 245).
Postoperative
hearing level
Preoperative hearing level
A B C Total (%)
A 30 7 - 37 (15.1)
B 16 27 2 45 (18.4)
C 17 30 22 69 (28.2)
D 50 30 14 94 (38.4)
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recurrence was 10.4 ± 3.6 (range 5-15 mm). Among these 12 
cases, five lesions were stable and continued to be observed, 
and 7 patients underwent surgical revision by TLa by reason 
of rapid growth tumour (> 2 mm/year) or aggravating symp-
toms. There was no evidence of tumour regrowth in the 6 
patients who underwent a near total tumour removal. 
Discussion
Over the last decades, the incidence of VS has increased to ap-
proximately 19 tumours per million per year. Several factors 
might be the cause of this increase, most important of which is 
the improvement in diagnostic equipment, i.e., magnetic reso-
nance imaging, in a context of increased life expectation. 
Along with the improvement of surgical techniques, the ac-
quiring importance of radiosurgery and the advancement of 
diagnostic equipment led to a change in the objectives of 
VS treatment. Modern VS surgery is reaching the goal of 
preservation of function. Although facial nerve preservation 
was the major concern in the past decades, currently hear-
ing preservation is the main challenge. To date, the choice 
of the surgical strategy depends on tumour size, hearing 
and facial nerve function, patient age and the presence of 
other disabling symptoms. The challenge and the matter of 
the actual debate is to achieve major tumour removal, with 
a minimal impairment of these functions. 
The extension of tumour removal is strictly related to tu-
mour size and to the adherence of the tumour to critical 
neurovascular structures 5  20-22. The analysis of the present 
series shows that over the years advancements such as the 
electrophysiological monitoring of facial function influ-
enced technical procedures and surgical outcomes. Over-
all in the present study, total tumour removal was reached 
in 99.4% of patients, with a higher rate of functional 
preservation in the last period. Moreover, the remaining 
0.6% of patients who underwent a near total removal 
was treated during period 3. In these cases (three stages 
3 and four stages 4, mean tumour size: 31.2 ± 9.8 mm), 
the presence of a tumour adherent to CPA structures led 
the surgeon to choose a conservative technique leaving in 
place a small residual. However, an average follow up of 
5 years demonstrated the stability of the lesions and none 
of the cases presented a growth of the residual. Therefore, 
in line with other reports we can state that near total tu-
mour resection might be a safe and effective method for 
preserving postoperative cranial nerve function without 
negatively impacting tumour control 23.
FN function
Several prognostic factors influence the postoperative 
FN function: tumour size, patient age, course of disease, 
previous treatment, surgical approach, intraoperative 
four-channel electromyography monitoring, FN displace-
ment pattern, tumour adhesion and heterogeneous or cys-
tic tumours 4 10 24 25. 
All surgeries were performed using a FN monitoring sys-
tem. FN anatomical integrity does not necessarily corre-
spond to good FN function. In our series, with 97.7% of 
FN anatomical integrity, good FN function was achieved 
only in 85.1% of patients. The good FN function rate var-
ied from 91.7% to 79.9%, and it was inversely proportion-
al to the tumour size. Thus, a larger tumour size implies a 
worse postoperative functional outcome. Recently, Esquia 
et al. 10 observed that the FN outcome is influenced by the 
displacement pattern and adhesion between the tumour 
and nerves. In addition, Bernat et al. 25 defined, as a crite-
ria for good FN prognosis, the use of supramaximal stim-
ulation threshold, that would increase the predictive value 
of monitoring during VS surgery. 
Several authors have reported the results of FN preserva-
tion by various surgical approaches 26-28. Our experience 
highlights that the choice of the approach has an influence 
Table V. Postoperative complications (n = 1006).
Complications Period 1
(1990-1996,
n = 268) (%)
Period 2
(1997-2001,
n = 299) (%)
Period 3
(2002-2006,
n = 439) (%)
Total 
(1990-2006, 
n = 1006) (%)
Mortality 1 (0.4) 1 (0.3) 1 (0.2) 3 (0.3)
CPA haematoma 2 (0.7) 2 (0.7) 1 (0.2) 5 (0.5)
Subarachnoid haemorrhage 1 (0.4) 1 (0.3) - 2 (0.2)
Lateral sinus thrombosis 1 (0.4) 1 (0.3) 1 (0.2) 3 (0.3)
Cerebellar oedema - 1 (0.3) 1 (0.2) 2 (0.2)
Pulmonary embolism 1 (0.4) - 1 (0.2) 2 (0.2)
Meningitis 5 (1.9) 4 (1.3) 3 (0.7) 12 (1.2)
Phlebitis 2 (0.7) 4 (1.3) 3 (0.7) 9 (0.9)
CSF leak 31 (11.6) 29 (9.7) 31 (7.1) 91 (9.0)
Revision 9 (3.4) 6 (2.0) 4 (0.9) 19 (1.9)
Conservative treatment 22 (8.2) 23 (7.7) 27 (6.2) 72 (7.2)
Lower cranial nerve palsy - 1(0.3) - 1 (0.1)
Subcutaneous abdominal haematoma 9 (3.4) 7 (2.3) 5 (1.1) 21 (2.1)
Recurrence 5 (1.9) 4 (1.3) 3 (0.7) 12 (1.2)
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on functional outcomes. TLa and TOa (applicable to all 
tumour sizes) lead to an easier identification of the FN, on 
the other hand, in VS approached by MF the FN preserva-
tion rate was lower (78.1%). Finally, the surgeon’s expe-
rience and postoperative rehabilitation training improved 
the results (87.6% in last period, 83.4% in intermediate 
period, and 78.4% in early period) without any change of 
the mean tumour size (p > 0.05). 
Hearing preservation
In the literature, data concerning hearing preservation vary 
from 18% to 96% of success 1-4 6 26 29 30. In our series, RSa 
was used in tumour < 15 mm in CPA with class A or B 
hearing level and free fundus, while MFa was preferred in 
intracanalicular tumours with class A or B hearing level. 
Preserved hearing and serviceable hearing were obtained 
in 61.6% and 33.5% of patients, respectively. Both of these 
two rates in period 3 were significantly higher than in the 
earlier periods (hearing preservation rate: 69.0% vs. 50.9%, 
p = 0.028; serviceable hearing preservation rate: 42.2% vs. 
21.8%, p = 0.010). As described, the preoperative pure tone 
average, free IAM fundus and tumour size 32,33 are predic-
tive factors for hearing preservation, but we believe that 
surgical experience may be crucial for hearing preserva-
tion, and in particular for intraoperative identification and 
protection of blood vessels and cochlear nerve.
In the last decade (2007-2016), the strategy for hearing 
preservation in VS removal has seen some changes. More 
frequently than before, subtotal or partial removal of the 
tumour via RSa is proposed to patients, even with a class 
3 VSs, followed by gamma knife radiotherapy. 
Complications
Mortality rates associated with VS removal have been de-
creasing from 20 to 0% during the past decades, but still 
remain significantly higher in patients over 70 years  33. 
Neurovascular disorders, brainstem injury and serious 
intracranial infections are the major causes of death. In 
our series, three patients deceased from CPA hemato-
ma, pulmonary embolism and cerebral haemorrhage. All 
life-threatening complications occurred in patients with 
VS higher than stage 3.
CSF leakage was the most frequent perioperative com-
plication in our series (9.0%). Our results confirm the re-
lation between CSF leakage and tumour size (14.7% in 
stage 4, 9.5% in stage 3, 7.4% in stage 2 and 4.5% in 
stage 1) 34 35,which is in contrast to what reported by Stieg-
lizt et al 36. However, its incidence is not related with the 
approach even if the occurrence of CSF leakage in TLA 
was lower (7.9%) than in the other approaches. Merkus 
et al. 35 reported 0.8% of CSF leakage after TLA during 
a 15-year period, suggesting some modification of clo-
sure techniques. Our incidence of CSF leakage decreased 
during the three periods (14.2% in early period > 9.0% in 
intermediate period > 5.9% in last period) demonstrating 
that the development of closure technique and surgeon’s 
experience helped to prevent this complication. Out of the 
four techniques of wound closure, the recent technique 
with a titanium plate anchored to the mastoid led to the 
most satisfactory results with a lower incidence of leak-
age compared to the average in the literature of 6.6% and 
15% 6. Consequently, the meningitis rate was 1.2%, which 
was lower than other reports (1.5%-2.6%) 34 36-38. 
The most serious complication in the present series was 
CPA hematoma. It usually occurs within the first 12 to 
24 hours and the key point is the immediate removal and 
decompression of the CPA hematoma, even without con-
firmation by CT scan. 
Conclusions
Many factors influence the surgical outcomes of sporadic 
VS. Our experience in a large series of 1006 sporadic VS 
treated over a 17-year period revealed that good function-
al outcomes depend on several critical variables, includ-
ing tumour size, surgical approach, surgeon’s experience 
and development of technique.
Over the years the surgical outcome of sporadic VS has 
improved, in particular regarding facial nerve function 
outcomes and cerebrospinal fluid (CSF) leaks, mainly 
due to the neuro-otological team’s experience. The actual 
challenge is hearing preservation after complete micro-
surgical removal of large VS, which depends on the expe-
rience gained on small VS removal.
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